Qichao Ni
Overview
Explore the profile of Qichao Ni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miao S, Ni Q, Fang J
Breast J
. 2025 Jan;
2024:4434466.
PMID: 39742384
This study aims to investigate the potential causal link between mitochondrial function and breast cancer using the Mendelian randomization (MR) analysis. The data used for this study were obtained from...
2.
Miao S, Bian C, Fang J, Wang S, You H, Zhou Y, et al.
Transl Cancer Res
. 2024 Nov;
13(10):5214-5232.
PMID: 39525038
Background: Tumor-associated macrophages play a critical role in the progression and immune response of triple-negative breast cancer (TNBC). Our study aimed to explore the characteristics of tumor-associated macrophages (TAMs) in...
3.
Li X, Gu Q, Sun P, Yang L, Zhang X, Lu B, et al.
Front Immunol
. 2024 Nov;
15:1487447.
PMID: 39493764
Background: Breast cancer (BC) remains a significant health issue globally and most common cause of mortality in women. Enhancing our understanding on biomarkers may greatly improve both diagnostic and therapeutic...
4.
Qian H, Ji R, Shen C, Wei Y, Sheng C, Ni Q, et al.
Aging (Albany NY)
. 2023 Dec;
15(24):14996-15024.
PMID: 38126976
Drug resistance in breast cancer (BC) is a clinical challenge. Exploring the mechanism and identifying a precise predictive biomarker for the drug resistance in BC is critical. Three first-line drug...
5.
Qiu J, Shen Z, Jiang G, Ni Q
Anticancer Agents Med Chem
. 2022 Aug;
23(4):470-477.
PMID: 35980070
Background: Triple-negative breast cancer (TNBC) is considered to be the most malignant subtype of breast cancer (BC). Heparanase (HPSE) has been reported to contribute to tumor development, but its potential...
6.
Kong X, Wang K, Wang S, Wang X, Jiang X, Guo Y, et al.
IEEE Internet Things J
. 2022 Jul;
8(21):15929-15938.
PMID: 35782184
During the outbreak of the Coronavirus disease 2019 (COVID-19), while bringing various serious threats to the world, it reminds us that we need to take precautions to control the transmission...
7.
Fang J, Li K, Huang C, Xue H, Ni Q
Am J Transl Res
. 2022 May;
14(4):2267-2279.
PMID: 35559394
Objective: Tamoxifen resistance of breast cancer (BC) is a significant hindrance in clinical therapy. The long-noncoding RNA (lncRNA) TTN-AS1 has been reported as a crucial tumor promoting factor in various...
8.
Fang J, Jiang G, Mao W, Huang L, Huang C, Wang S, et al.
Bioengineered
. 2022 Jan;
13(2):3707-3723.
PMID: 35094653
Breast cancer is the leading cause of cancer-related death among females, which is required to be solved urgently. Recent studies have found significant changes in a large number of genes...
9.
Wang G, Ni K, Gu C, Huang J, Chen J, Wang X, et al.
Oncol Rep
. 2021 Jul;
46(2).
PMID: 34278497
Erythropoietin‑producing hepatocellular receptors (Ephs) comprise the largest subfamily of receptor tyrosine kinases and have been reported to be involved in a variety of biological cellular processes, including tumorigenesis and cancer...
10.
Li Y, Xue D, Lu L, Chen X, Lu P, Ni Q
Minerva Med
. 2021 Jul;
113(3):597-599.
PMID: 34236158
No abstract available.